SCHEMBL4842718

SCHEMBL4842718

FC(F)(F)c1ccc(Nc2cc(-c3cccc4ncccc34)ncn2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 4/20 0.60
ABL1 P00519 5/20 0.58
BCR P11274 5/20 0.58
KDR P35968 1/20 0.47
CYP1A2 P05177 3/20 0.46
CYP2D6 P10635 3/20 0.46
CYP2C19 P33261 3/20 0.46
CYP3A4 P08684 2/20 0.46
MAPK1 P28482 2/20 0.46
HPGD P15428 1/20 0.46
TNNI3K Q59H18 1/20 0.45
CLK4 Q9HAZ1 3/20 0.45
CDC7 O00311 1/20 0.45
ROCK2 O75116 1/20 0.45
MAP4K4 O95819 1/20 0.45
PIM1 P11309 1/20 0.45
PRKACA P17612 1/20 0.45
CDK2 P24941 1/20 0.45
GSK3B P49841 1/20 0.45
HIPK2 Q9H2X6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4842241 0.83 TRPV1 (0.61) TRPV1ABL1BCRCYP1A2CYP2D6
SCHEMBL4832755 0.81 ABL1 (0.63) TRPV1ABL1BCRKDRCYP1A2
SCHEMBL5801193 0.80 TRPV1 (0.67) TRPV1ABL1BCRCYP1A2CYP2D6
SCHEMBL5801787 0.80 TRPV1 (0.67) TRPV1ABL1BCRCYP1A2CYP2D6
SCHEMBL1011763 0.80 TRPV1 (0.64) TRPV1ABL1BCR
SCHEMBL5347641 0.78 ABL1 (0.62) TRPV1ABL1BCRCYP1A2CYP2D6
SCHEMBL4832759 0.77 TRPV1 (0.87) TRPV1ABL1BCRTNNI3K
SCHEMBL4837497 0.77 TRPV1 (0.76) TRPV1ABL1BCRCYP1A2CYP2D6
SCHEMBL6033681 0.76 TRPV1 (0.61) TRPV1ABL1BCRCYP1A2CYP2D6
SCHEMBL13868105 0.75 TRPV1 (1.00) TRPV1ABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7314933-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2008-01-01 US claimed
EP-1807418-A2 SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLES AS VANILLOID RECEPTOR LIGANDS AND THEIR USES AS MEDICAMENT Amgen, Inc (US) 2007-07-18 EP claimed
EP-1685124-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2006-08-02 EP claimed
WO-2006047492-A2 SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLES AS VANILLOID RECEPTOR LIGANDS AND THEIR USES AS MEDICAMENT AMGEN INC. (US) 2006-05-04 WO claimed
US-20060089360-A1 Inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis; 6-(1H-indol-5-yl)-N-(4-(trifluoromethyl)phenyl)-4-pyrimidinamine AMGEN INC. 2006-04-27 US claimed
WO-2006038041-A1 BESYLATE SALTS OF SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2006-04-13 WO claimed
US-20050197342-A1 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain HOLLINGWORTH GREGORY J (GB) 2005-09-08 US claimed
WO-2005047280-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO claimed
WO-2005047279-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO claimed
US-7314933-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2008-01-01 US disclosed
US-7314933-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2008-01-01 US disclosed
EP-1685124-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2006-08-02 EP disclosed
WO-2006038041-A1 BESYLATE SALTS OF SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2006-04-13 WO disclosed
US-20050197342-A1 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain HOLLINGWORTH GREGORY J (GB) 2005-09-08 US disclosed
WO-2005047280-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO disclosed
WO-2005047279-A1 SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2005-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197342-A1 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain OPRL1, OPRK1, CNR1 TRPV1 11/4885ABL1 989/4885BCR 1760/4885
US-20060089360-A1 Inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis; 6-(1H-indol-5-yl)-N-(4-(trifluoromethyl)phenyl)-4-pyrimidinamine TRPV1, TRPA1, TRPV3 TRPV1 1/4885ABL1 832/4885BCR 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.